Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A 1-year, open-label extension study

BJU International

Volumn 107, Issue 7, 2011, Pages 1110-1116

  Donatucci, Craig F ^a   Brock, Gerald B ^b   Goldfischer, Evan R ^c   Pommerville, Peter J ^d   Elion Mboussa, Albert ^e   Kissel, Jay D ^e   Viktrup, Lars ^e  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c Hudson Valley Urology   (United States)

^d Can Med Clinical Research Inc   (Canada)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

benign prostatic hyperplasia; erectile dysfunction; long term; prostate; tadalafil

Indexed keywords

PLACEBO; PROSTATE SPECIFIC ANTIGEN; TADALAFIL;

ADULT; AMNESIA; ARTICLE; BACKACHE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COUGHING; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ERECTILE DYSFUNCTION; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; HYPERTENSION; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PENIS ERECTION; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEXUAL BEHAVIOR; SINUSITIS; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; CARBOLINES; DRUG ADMINISTRATION SCHEDULE; EPIDEMIOLOGIC METHODS; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PROSTATIC HYPERPLASIA; PROSTATISM; TREATMENT OUTCOME;

EID: 79953216653     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09687.x     Document Type: Article

References (17)

1. th ed. Philadelphia, PA: W.B. Saunders Company, 2002: 1297-330
2. Berry SJ, Coffey DS, Walsh PC, Ewing LL,. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9 (Pubitemid 14026148)
3. Wei JT, Calhoun E, Jacobsen SJ,. Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005; 173: 1256-61 (Pubitemid 40380548)
4. American Urological Association (AUA) Benign Prostatic Hyperplasia (BPH) Guideline Update Panel: Guideline on the Management of Benign Prostatic Hyperplasia (BPH). 2006 Available at: http://www.auanet.org/content/guidelines- and-quality-care/clinicalguidelines.cfm?sub=bph. Accessed May 2009
5. McConnell JD, Roehrborn CG, Bautista OM, et al,. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98 (Pubitemid 37542987)
6. Roehrborn CG, Siami P, Barkin J, et al,. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008; 179: 616-21; discussion 21
7. Debruyne F, Koch G, Boyle P, et al,. Comparison of a phytotherapeutic agent (Permixon) with an alpha- blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Eur Urol 2002; 41: 497-506; discussion 7
8. McVary KT, Monnig W, Camps JL, Jr, Young JM, Tseng LJ, van den Ende G,. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007; 177: 1071-7 (Pubitemid 46216352)
9. McVary KT, Roehrborn CG, Kaminetsky JC, et al,. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177: 1401-7 (Pubitemid 46435965)
10. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L,. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008; 180: 1228-34
11. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E,. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008; 53: 1236-44
12. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549-57; discussion 64
13. Barry MJ, Williford WO, Chang Y, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995; 154: 1770-4
14. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK,. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association. Med Care 1995; 33: AS145-55
15. Porst H, Rajfer J, Casabe A, et al,. Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J Sex Med 2008; 5: 2160-9
16. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G,. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. Urology 2009; 74: 1318-22
17. Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C,. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004; 46: 488-94; discussion 95